Soligenix shares are trading higher after the company on Monday announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Portfolio Pulse from Benzinga Newsdesk
Soligenix shares surged following the FDA's grant of orphan drug designation to MarVax's active ingredient for MARV infection prevention and post-exposure prophylaxis.
April 16, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soligenix's stock price is expected to rise in the short term due to the FDA's orphan drug designation for MarVax.
The FDA's orphan drug designation is a positive regulatory milestone that can enhance investor confidence in Soligenix, potentially leading to increased stock price in the short term due to perceived future benefits and exclusivity advantages associated with the designation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100